Therefore, for the first time using molecular and bioinformatic approaches, we examined whether alterations in gene expression of these pathways can influence the risk of recurrence (Ultralow, Low, High 1, and High 2), and progression of molecular subtypes (Luminal A, Luminal B, HER2, and Basal) in breast cancer [13]. Here, ERBB2 is linked to breast cancer.